Reuters logo
AstraZeneca licenses inflammatory disease candidate to Allergan
October 3, 2016 / 6:26 AM / a year ago

AstraZeneca licenses inflammatory disease candidate to Allergan

LONDON, Oct 3 (Reuters) - Britain’s AstraZeneca said it had licensed a potential medicine for inflammatory diseases to Allergan for an upfront payment of $250 million and potential additional payments of up to $1.27 billion.

AstraZeneca said the drug developed by its global biologics research and development arm MedImmune was being testing as a treatment for moderate-to-severe Crohn’s disease and was ready to start trials for ulcerative colitis.

Amgen Inc, which has been collaborating with MedImmune on developing the medicine, will receive a third of all payments and royalties received from Allergan, AstraZeneca said on Monday.

Reporting by Paul Sandle; editing by Sarah Young

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below